Management of metastatic castration-resistant prostate cancer

A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel

Sergio Baldari, Giuseppe Boni, Roberto Bortolus, Orazio Caffo, Giario Conti, Giuseppe De Vincentis, Fabio Monari, Giuseppe Procopio, Daniele Santini, Ettore Seregni, Riccardo Valdagni

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC, treatment with radium-223 has been associated with survival benefit, regardless of prior docetaxel use, and also has a positive impact on symptomatic skeletal events and quality of life. Radium-223 is best suited for patients with symptomatic mCRPC and bone-predominant disease and no visceral metastases, and may lead to better outcomes when given early in the course of the disease. An expert multidisciplinary panel convened in Milan, Italy to review the current best-evidence literature on radium-223 and to convey their personal expertise with the use of radium-223 and identify possible strategies for best practice. This article summarizes the best available evidence for the use of radium-223, discusses the essential role of the multidisciplinary team in delivering effective treatment for mCRPC, clarifies pre- and post-treatment evaluation and monitoring, and outlines future scenarios for radium-223 in the treatment of men with MCRPC.

Original languageEnglish
Pages (from-to)43-51
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume113
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Radium
Castration
Expert Testimony
Prostatic Neoplasms
Bone Neoplasms
docetaxel
Neoplasm Metastasis
Therapeutics
Alpha Particles
Bone and Bones
Bone Diseases
Practice Guidelines
Radioisotopes
Italy
Quality of Life
Calcium
Survival

Keywords

  • Alpha emitters
  • Bone metastases
  • Metastatic castration-resistant prostate cancer
  • Radiopharmaceuticals
  • Radium-223
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Management of metastatic castration-resistant prostate cancer : A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. / Baldari, Sergio; Boni, Giuseppe; Bortolus, Roberto; Caffo, Orazio; Conti, Giario; De Vincentis, Giuseppe; Monari, Fabio; Procopio, Giuseppe; Santini, Daniele; Seregni, Ettore; Valdagni, Riccardo.

In: Critical Reviews in Oncology/Hematology, Vol. 113, 01.05.2017, p. 43-51.

Research output: Contribution to journalReview article

@article{195f7fb752d143ae849e3f6cee3b6ef8,
title = "Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel",
abstract = "Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC, treatment with radium-223 has been associated with survival benefit, regardless of prior docetaxel use, and also has a positive impact on symptomatic skeletal events and quality of life. Radium-223 is best suited for patients with symptomatic mCRPC and bone-predominant disease and no visceral metastases, and may lead to better outcomes when given early in the course of the disease. An expert multidisciplinary panel convened in Milan, Italy to review the current best-evidence literature on radium-223 and to convey their personal expertise with the use of radium-223 and identify possible strategies for best practice. This article summarizes the best available evidence for the use of radium-223, discusses the essential role of the multidisciplinary team in delivering effective treatment for mCRPC, clarifies pre- and post-treatment evaluation and monitoring, and outlines future scenarios for radium-223 in the treatment of men with MCRPC.",
keywords = "Alpha emitters, Bone metastases, Metastatic castration-resistant prostate cancer, Radiopharmaceuticals, Radium-223, Survival",
author = "Sergio Baldari and Giuseppe Boni and Roberto Bortolus and Orazio Caffo and Giario Conti and {De Vincentis}, Giuseppe and Fabio Monari and Giuseppe Procopio and Daniele Santini and Ettore Seregni and Riccardo Valdagni",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.critrevonc.2017.03.001",
language = "English",
volume = "113",
pages = "43--51",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Management of metastatic castration-resistant prostate cancer

T2 - A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel

AU - Baldari, Sergio

AU - Boni, Giuseppe

AU - Bortolus, Roberto

AU - Caffo, Orazio

AU - Conti, Giario

AU - De Vincentis, Giuseppe

AU - Monari, Fabio

AU - Procopio, Giuseppe

AU - Santini, Daniele

AU - Seregni, Ettore

AU - Valdagni, Riccardo

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC, treatment with radium-223 has been associated with survival benefit, regardless of prior docetaxel use, and also has a positive impact on symptomatic skeletal events and quality of life. Radium-223 is best suited for patients with symptomatic mCRPC and bone-predominant disease and no visceral metastases, and may lead to better outcomes when given early in the course of the disease. An expert multidisciplinary panel convened in Milan, Italy to review the current best-evidence literature on radium-223 and to convey their personal expertise with the use of radium-223 and identify possible strategies for best practice. This article summarizes the best available evidence for the use of radium-223, discusses the essential role of the multidisciplinary team in delivering effective treatment for mCRPC, clarifies pre- and post-treatment evaluation and monitoring, and outlines future scenarios for radium-223 in the treatment of men with MCRPC.

AB - Radium-223, a calcium mimetic bone-seeking radionuclide that selectively targets bone metastases with alpha particles, is approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. In patients with mCRPC, treatment with radium-223 has been associated with survival benefit, regardless of prior docetaxel use, and also has a positive impact on symptomatic skeletal events and quality of life. Radium-223 is best suited for patients with symptomatic mCRPC and bone-predominant disease and no visceral metastases, and may lead to better outcomes when given early in the course of the disease. An expert multidisciplinary panel convened in Milan, Italy to review the current best-evidence literature on radium-223 and to convey their personal expertise with the use of radium-223 and identify possible strategies for best practice. This article summarizes the best available evidence for the use of radium-223, discusses the essential role of the multidisciplinary team in delivering effective treatment for mCRPC, clarifies pre- and post-treatment evaluation and monitoring, and outlines future scenarios for radium-223 in the treatment of men with MCRPC.

KW - Alpha emitters

KW - Bone metastases

KW - Metastatic castration-resistant prostate cancer

KW - Radiopharmaceuticals

KW - Radium-223

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85018475039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018475039&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.03.001

DO - 10.1016/j.critrevonc.2017.03.001

M3 - Review article

VL - 113

SP - 43

EP - 51

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -